IL6R and allergic disease: Third, a potential limitation of TCZ when considered for the treatment of asthma or other allergic diseases is that it blocks both mIL‐6R and sIL‐6R,85 that is, it inhibits both IL‐6 classic signalling and trans‐signalling.